At C-Path’s International Neonatal Consortium, we believe that meaningful progress in neonatal drug development happens when experts from diverse sectors come together to create practical solutions. One such example is the Neonatal Adverse Event Severity Scale (NAESS)—a tool developed through INC’s collaborative efforts to bring more consistency and clarity to neonatal clinical trials.
We are incredibly grateful to Oakhill Bio and Dr. Victoria Niklas for taking NAESS a step further by developing a user-friendly app that makes this tool more accessible to industry and academic researchers. Their work exemplifies the power of partnership in translating scientific frameworks into real-world impact for neonatal drug development.
This kind of innovation—driven by shared purpose and collaboration—strengthens the ecosystem needed to bring new therapies to the most vulnerable patients. Thank you, Oakhill Bio, for your commitment to advancing neonatal research.
